Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Accumulated Expenses (2024 - 2025)

Historic Other Accumulated Expenses for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to $99898.0.

  • Neuphoria Therapeutics' Other Accumulated Expenses rose 21613.29% to $99898.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $99898.0, marking a year-over-year increase of 21613.29%. This contributed to the annual value of $278149.0 for FY2025, which is N/A changed from last year.
  • Latest data reveals that Neuphoria Therapeutics reported Other Accumulated Expenses of $99898.0 as of Q4 2025, which was up 21613.29% from $112028.0 recorded in Q3 2025.
  • In the past 5 years, Neuphoria Therapeutics' Other Accumulated Expenses ranged from a high of $278149.0 in Q2 2025 and a low of $31600.0 during Q4 2024